BIOLOGICAL MARKERS IN DIAGNOSIS OF ADHD BIOLOGICALLY BASED NOSOLOGY FOR ADHD
Investigators at Oregon Health and Science University and other centers attempt to refine subtyping of childhood ADHD by using biologically based behavioral temperament types. Groups were validated using 3 external validators: cardiac measures of respiratory sinus arrhythmia, CNS functioning via functional MRI, and clinical outcomes at 1-year follow-up. Three novel types of ADHD were recognized: mild (normative emotion regulation), surgent (extreme levels of positive approachmotivation), and irritable (extreme levels of negative emotionality, anger, and poor soothability). These types were stable over time and showed unique patterns of cardiac physiological response, resting-state functional brain connectivity, and clinical outcomes. This biologically informed temperament-based typology is thought to provide a superior description of heterogeneity in the ADHD population than any current classification. COMMENTARY. The use of a combination of biological markers may help to reduce heterogeneity and to identify homogeneous phenotypes of ADHD. A consensus report of the World Federation of Societies of Biological Psychiatry (WFSBP) task force on biological markers and the World Federation of ADHD determined in 2012 that no reliable ADHD biomarker had been described to date, but some promising candidates (e.g. olfactory sensitivity, substantial echogenicity) exist. The development of ADHD markers is hindered by sample heterogeneity due to etiological and phenotypic complexity and age-dependent co-morbidities [1] . COMMENTARY. The FDA approved the Neuropsychiatric EEG-Based ADHD Assessment Aid (NEBA) medical device in 2013 to be used as confirmatory support or to pursue further testing after an evaluation for ADHD, in a child aged 6-17. The device was not to be used as a stand alone method of diagnosis of ADHD.
The AAN, in an Evidence-Based Practice Advisory, concludes that it is highly likely that EEG theta-beta power ratio and EEG frontal beta power correctly identify patients with ADHD (accuracy 89% to 94%) as compared to a clinical evaluation. The AAN recommends that the EEG test should not be used in place of a standard clinical evaluation, because of the risks of misdiagnosis of 6-15% when using the theta/beta ratio. There is neither evidence for, nor against the use of theta/beta EEG power ratio either to confirm a diagnosis of ADHD, nor to support further testing. Whether comorbid disorders such as ODD have similar changes in the theta/beta ratios that mimic the reported finding in ADHD is not known [1] .
A recent report of spectral analysis of EEGs on 28 normal and 58 ADHD children, aged 6 to 14 years, found TBR was higher in ADHD subjects, with lower beta but no difference in theta power over Broca's area. Beta-1 power over Broca's area was the best diagnostic test, with sensitivity 0.86 and specificity 0.57. The EEG beta-1 power and TBR assist in confirming the diagnosis of ADHD in a sample with moderate pretest probability of ADHD [2] .
The present symptomatic method of diagnosis, based on parent and teacher evaluations, is relatively accurate in children with the hyperactive-impulsive subtype of ADHD but less so with the inattentive type. A more objective test such as EEG if validated could be a valuable aid in the diagnosis and management of ADHD. The significance of seizure discharges in approximately 25% of sleep-deprived EEGs in ADHD children is further evidence of the utility of the EEG in ADHD management [3] .
